Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 10Phase 1/2 7Phase 1 7Phase 2/3 3Phase 4 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

Zoledronic Acid 28Saline Solution 26Metformin 25Dexamethasone 25Cyclophosphamide 23Cytarabine 22Bupivacaine 20Sodium Chloride 18Vincristine 17Methotrexate 17Letrozole 17Propofol 15Morphine 15Doxorubicin 15Cisplatin 15Prednisolone 14Docetaxel 14Dexmedetomidine 14Bevacizumab 14Oxycodone 13Imiquimod 13Fentanyl 13Capecitabine 13Rituximab 12Mercaptopurine 12Fluorouracil 12Granulocyte Colony-Stimulating Factor 11Everolimus 11Asparaginase 11Acetaminophen 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × Gemtuzumab × Clear all
NCT01041040 2013-07-31

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 4 Completed
200 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00304447 2009-07-29

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 4 Completed
30 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡